CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy. Thirty to forty percent of DLBCL patients still experience relapse or develop refractory disease even with standard immunochemotherapy, leading to a poor prognosis. Currently, although several gene-based classificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jie, Zhu, Xiaoquan, Zhao, Yanyang, Zhou, Qi, Qi, Ruomei, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021264/
https://www.ncbi.nlm.nih.gov/pubmed/33833551
http://dx.doi.org/10.2147/PGPM.S301718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021264/
https://www.ncbi.nlm.nih.gov/pubmed/33833551
http://dx.doi.org/10.2147/PGPM.S301718

Ejemplares similares